InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

InspireMD Price Performance

NSPR stock opened at $2.25 on Tuesday. The stock has a market capitalization of $52.79 million, a P/E ratio of -2.08 and a beta of 0.84. The business has a 50-day moving average of $2.48 and a 200-day moving average of $2.73. InspireMD has a fifty-two week low of $0.96 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period in the prior year, the firm earned ($0.60) earnings per share. Equities analysts expect that InspireMD will post -0.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NSPR. Marshall Wace LLP acquired a new position in InspireMD during the second quarter valued at approximately $4,670,000. Nantahala Capital Management LLC boosted its position in InspireMD by 16.9% during the fourth quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock valued at $5,807,000 after purchasing an additional 298,406 shares during the last quarter. Northern Trust Corp acquired a new position in InspireMD during the fourth quarter valued at approximately $80,000. Avestar Capital LLC acquired a new position in InspireMD during the third quarter valued at approximately $65,000. Finally, Renaissance Technologies LLC acquired a new position in InspireMD during the second quarter valued at approximately $36,000. 44.78% of the stock is owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.